Table 1 Characteristics of PD patients and healthy controls
Controls (n = 97) | PD patients (n = 101) | Z/T | P | |
|---|---|---|---|---|
Sex (male, %) | 52 (53.1%) | 55 (56.1%) | 0.185 | 0.667 |
Age (years) | 67.5 (56.75 ~ 75) | 68.5 (59 ~ 77) | −0.587 | 0.557 |
Smoking (male-%) | 5 (5.1%) | 13 (13.3%) | 3.915 | 0.048 |
Drinking (male-%) | 1 (1%) | 8 (8.2%) | – | 0.035△ |
Hypertension (male-%) | 32 (32.7%) | 19 (19.4%) | 4.479 | 0.034 |
Statin therapy | 13 (13.3%) | 27 (27.6%) | 6.156 | 0.013 |
BMI (kg/m2) | 24.69 (22.56 ~ 27.39) | 23.02 (21.5 ~ 24.63) | −3.812 | < 0.001 |
WBCs (×109/L) | 5.53 ± 1.16 | 5.65 ± 1.12 | −0.713 | 0.477 |
Neutrophils (×109/L) | 3.21 (2.62 ~ 3.88) | 3.5 (2.94 ~ 4.37) | −2.646 | 0.008 |
Lymphocytes (×109/L) | 1.68 (1.32 ~ 2.11) | 1.38 (1.15 ~ 1.79) | −3.326 | 0.001 |
Monocytes (×109/L) | 0.39 (0.32 ~ 0.44) | 0.36 (0.31 ~ 0.48) | −0.06 | 0.952 |
Hb (×109/L) | 161.69 ± 20.26 | 157.87 ± 13.98 | 1.539 | 0.126 |
UA (μmol/L) | 348.85 ± 77.51 | 303.09 ± 80.16 | 4.062 | < 0.001 |
TC (mmol/L) | 4.97 (4.27 ~ 5.5) | 4.09 (3.72 ~ 4.8) | −5.148 | < 0.001 |
TG (mmol/L) | 1.47 (1.15 ~ 2.24) | 1.18 (0.87 ~ 1.66) | −3.613 | < 0.001 |
HDL-C (mmol/L) | 1.32 ± 0.29 | 1.17 ± 0.29 | 3.488 | 0.001 |
LDL-C (mmol/L) | 2.84 ± 0.82 | 2.45 ± 0.69 | 3.606 | < 0.001 |
MHR (×109/mmol) | 0.3 (0.23 ~ 0.38) | 0.33 (0.25 ~ 0.43) | −1.822 | 0.068 |
NHR (×109/mmol) | 2.48 (1.74 ~ 3.34) | 3.18 (2.33 ~ 4.04) | −3.734 | < 0.001 |
NLR (×109/mmol) | 2.01 (1.52 ~ 2.54) | 2.59 (2.02 ~ 3.18) | −4.599 | < 0.001 |
Parkinson’s drugs | ||||
Compound levodopa (%) | / | 77 (78.57) | / | / |
DR agonist (%) | / | 29 (29.59) | / | / |
MAO-B inhibitors (%) | / | 28 (28.57) | / | / |
COMT inhibitors (%) | / | 8 (8.16) | / | / |
Anticholinergic drugs (%) | / | 8 (8.16) | / | / |